Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Pharmexcil Revises Downward Drug Export Forecast

This article was originally published in PharmAsia News

Executive Summary

India's drug-exporting promoter forecasts a 10 percent decline in the growth of pharmaceutical exports in the 2008-2009 period due to the global economic slowdown. The Pharmaceutical Export Promotion Council revised its previous forecast for exports for the period, at $8.97 billion, to just $8.25 billion. That translates to a 13.9 percent growth rate rather than 23.9 predicted earlier. Pharmexcil cited the tightened credit market as a major contributor to the revised prospects, with some developing countries having to cancel expansions of their health care programs. (Click here for more

You may also be interested in...

Indian Exporters Fume As EU Seizes Goods-In-Transit Claiming Patent Violations

MUMBAI - Large consignments of drug exports from India routed through the European Union are being confiscated on allegations of violation of local European patent laws. As per the EU patent laws, such exports are also termed as counterfeit drugs, experts say

US COVID-19 Vaccine Adcomm: First Take-Aways

From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.

QUOTED. 23 October. Dan Buehner.

Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts